| Literature DB >> 29411697 |
Xiaofang Zuo1, Zhipeng Huo1, Dongwei Kang1, Gaochan Wu1, Zhongxia Zhou1, Xinyong Liu1, Peng Zhan1.
Abstract
INTRODUCTION: To deal with the rapid emergence of drug resistance challenges, together with the difficulty to eradicate the virus, off-target effects and significant cumulative drug toxicities, it is still imperative to develop next-generation anti-HIV agents with novel chemical classes or new mechanisms of action. AREAS COVERED: We primarily focused on current strategies to discover novel anti-HIV agents. Moreover, examples of anti-HIV lead compounds were mainly selected from recently patented publications (reported between 2014 and 2017). In particular, 'privileged structure'-focused substituents decorating approach, scaffold hopping, natural-product diversification and prodrug are focused on. Furthermore, exploitation of new compounds with unexplored mechanisms of action and medicinal chemistry strategies to deplete the HIV reservoir were also described. Perspectives that could inspire future anti-HIV drug discovery are delineated. EXPERT OPINION: Even if a large number of patents have been disclosed recently, additional HIV inhibitors are still required, especially novel chemical skeletons displaying a unexploited mechanism of action. Current medicinal chemistry strategies are inadequate, and appropriate and new methodologies and technologies should be exploited to identify novel anti-HIV drug candidates in a time- and cost- effective manner.Entities:
Keywords: AIDS; HIV-1; drug design; hit-to-lead optimization; inhibitors; medicinal chemistry
Mesh:
Substances:
Year: 2018 PMID: 29411697 DOI: 10.1080/13543776.2018.1438410
Source DB: PubMed Journal: Expert Opin Ther Pat ISSN: 1354-3776 Impact factor: 6.674